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Abstract
The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer and the
subsequent development of HER2-targeted therapies, have dramatically improved clinical outcomes for women with
early-stage and advanced HER2-positive breast cancer (BC).
HER-2 targeted therapies represent a major step forward in achieving the goal of delivering individualized targeted
therapy for BC, and trastuzumab was the first anti-HER-2 strategy to be approved for treatment of HER-2 positive BC.
This review discusses the treatment of metastatic HER2-positive BC and describes efficacy and safety of novel anti-HER2
target therapies in first-line metastatic settings and the future challenges include refining such treatments, reducing
toxicity and simultaneously developing innovative therapies. Furthermore, combinations of trastuzumab and drugs
targeting the downstream pathway are described.
In the next future will be possible to use an ample armamentarium of combination therapies directed against HER2
and key signaling components integrated in the HER network. This approach will allow clinicians to tailor the
management of the individual patient on the basis of tumor- specific biomarker profiles.
There is an urgent need for prospective biomarker-driven trials to identify patients for whom targeting is cost-effective.
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Background
About 20 % of invasive breast cancers (BC) are HER2-
positive and characterized by amplification and/or overex-
pression of HER2, a transmembrane receptor with tyrosine
kinase (TK) activity, resulting in HER2 gene amplification
on chromosome 17. This subtype of BC shows an intrinsic
malignancy and has a poor prognosis in the absence of
specific treatment. About 10 % of the cases will be diag-
nosed as metastatic disease and the 5-year overall survival
(OS) in these patients achieves 20 % (historical median
survival range 16–29 months), of which 2–5 % are long-
term survivors [1, 2] On the other hand HER2 espression
identifies patients who may benefit from anti-HER2
targeted therapies [3–11].
Trastuzumab, a humanized monoclonal antibody that
selectively binds to the HER2 on the surface of tumour
cells, when added to chemotherapy in the first-line ad-
vanced treatment of HER2-positive BC is associated with
a significantly reduced risk of progression and death
compared to chemotherapy alone [12–16].
However, despite these deep therapeutic advances, the
progression free survival (PFS), and OS of patients treated
with trastuzumab and chemotherapy-based regimens for
metastatic BC (MBC) is about 7 months (vs about 5 months
without trastuzumab) and 25 months (in contrast to
20 months without trastuzumab) respectively [17, 18].
In the last 5 years we are witnessing an exponential
development of new anti HER2 molecules and results of
their activity in terms of outcome for the advance tumor
are very exciting.
In this article, we will analyze the most relevant
aspects related to new developments with anti-HER2
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therapies and the more recent clinical evidences and
therapeutic strategies with the modern use of biological
anti HER2 drugs at the first progression of BC patients.
HER2: the beginning of the story
With regard to blocking gene expression, the most
significant strategy in HER2-targeted therapies have
been made using monoclonal antibodies directed against
the extracellular domain of the HER2 protein, named tras-
tuzumab. Binding with high affinity to the extracellular
domain of HER2, trastuzumab inhibits the proliferation of
tumour cells that overexpress HER2. It demonstrated anti-
tumour effects when administered as a single agent, and
additive and synergistic effects when administered in
combination with a range of antineoplastic agents (1).
After the first phase II trials in which it was underlined
clinical efficacy of trastuzumab-including chemotherapy
(anthracyclines, paclitaxel) at the first recurrense of disease,
the successive evolution in clinic was to compare chemo-
therapy alone versus a combination of chemotherapy plus
trastuzumab as first-line therapy in MBC patients whose
tumors overexpressing HER2 [17–19]. The addition of tras-
tuzumab to chemotherapy significantly increased overall
response rate [ORr (50 vs. 32 %, p < 0.001)], duration of
response [DR (9.1 vs. 6.1 months, p < 0.001)], time to
progression [TTP (7.4 vs. 4.6 months, p < 0.001)], time to
failure [TTF (6.9 vs 4.5 months, p < 0.001)]. The addition of
trastuzumab to paclitaxel increased the ORr from 17 to
41 % (p < 0.001), the DR from 4.5 to 10.5 months (p < 0.01),
the TTP from 3.0 to 6.9 months (p < 0.001) and the TTF
from 2.9 to 5.8 months (p < 0.001). The addition of
trastuzumab to adriamycin plus cyclophosphamide
(AC) increased the RR from 42 to 56 % (p = 0.02), the
DR from 6.7 to 9.1 months (p = 0.005), the TTP from
6.1 to 7.8 months (p < 0.001) and the TTF from 5.6 to
7.2 months (p < 0.001). The median OS for patients
who received trastuzumab and chemotherapy combin-
ation was 25 months vs. 20 months for those who
received chemotherapy alone (p = 0.046). This result is
even more significant in light of the fact that two-
thirds of the women who are progressive on chemo-
therapy alone arm went on to receive open-label
trastuzumab on a compassionate-use protocol [18].
Therefore, the magnitude of the survival advantage
may have been diminished due to this crossover bias.
The quality of life (QoL) was also studied using stan-
dardized QoL questionnaires.
Overall, there was a statistically significant improve-
ment in fatigue and global QoL in the chemotherapy
plus trastuzumab group [20]. As seen in previous experi-
ences, patients with immunoistochimical (IHC) 3+ stain-
ing appeared to benefit more from trastuzumab than
those in the IHC 2+ subgroup. Furthermore, significant
benefit was seen only in patients whose tumors were
positive for gene amplification by fluorence in situ hibri-
dation (FISH) [21]; in these subgroups of patients the
OS was improved with the use of trastuzumab combined
to chemotherapy (Odds Ratio 0.71, 95 % CI:0.54 to 0.92;
p = 0.009) compared to chemotherapy alone. No such
differences were noted in the FISH negative subgroup. It
must be kept in mind, however, that these results were
derived from a retrospective subset analysis, and the
number of FISH-negative subjects was small (n = 108).
Based upon the results of these phase II and III trials,
trastuzumab was approved for use in MBC patients
with HER2-amplified or overexpressed as monotherapy
(second line or later) or in combination with paclitaxel
(first-line) by the United States FDA in September 1998.
Other combinations showed to be effective such as
docetaxel plus trastuzumab [16, 22] and vinorelbine plus
trastuzumab [23].
Multi-targeted HER2 agents: the new frontiers
Additional therapies targeted to other HER2 pathways to
be used in combination with trastuzumab are being ex-
plored both in adjuvant and metastatic settings [24, 25].
HER2-targeted treatment can be used as single- (e.g.
trastuzumab, pertuzumab and trastuzumab-MCC-DM1)
or multi-targeted HER2 agents (e.g. pertuzumab, lapati-
nib) combined with standard sistemic treatment (chemo-
therapy or hormone therapy, e.g. taxane, anthracyclines,
anastrozole, letrozole).
With regard to the management of advanced HER2-
positive BC, trastuzumab, pertuzumab, trastuzumab
emtansine (formerly known as T-DM1) and lapatinib
are approved as standard care for inhibiting HER2
activity in the treatment of HER2 positive MBC and for
increasing the incidence of PFS, OS and overall
response rate (ORr) when compared with chemother-
apy alone or standard anti-HER2 molecule [26–28, 29–
31]. But to date, only the combining of trastuzumab
and pertuzumab have indication in the first-line
setting.
The first recurrence in HER2 positive MBC
patients: what do we offer today?
What to do and what not to do at the first recurrence in
HER2 positive MBC patients?
One important study showed us what not to do for first-
line MBC: the MA-31 trial compared lapatinib/taxane
followed by lapatinib vs trastuzumab/taxane followed by
trastuzumab in 600 patients; it found a PFS detriment for
lapatinib/taxane at the interim analysis [31]. Moreover,
this combination showed an increased febrile neutropenia
and grade 3 or higher grade of diarrhea. We need to
remember these data in clinical decision-making when
lining up our therapeutic options for women at the firse
appearence of HER2 positive disease.
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The survival bar has now been raised to over 15 months
with the combination of pertuzumab plus trastuzumab.
The CLEOPATRA study [26, 32] showed the big power of
adding a second antibody, pertuzumab, to trastuzumab as
first-line metastatic therapy. Pertuzumab, binds to HER2
receptor but at a different site to trastuzumab, and is able
to inhibit ligand-induced dimerization of HER2 with its
receptor partners [33]. Preclinical experiments showed
that pertuzumab and trastuzumab produced a more-
complete blockade of the HER signaling network when
combined, and were more effective in HER2-positive
tumor xenografts, than either antibody alone [34].
The study assessed the efficacy and safety of three-
weekly pertuzumab (fixed loading dose of 840 mg iv.,
followed by 420 mg iv.) with trastuzumab (8 mg/kg iv.,
followed by a maintenance dose of 6 mg/kg iv.) plus doce-
taxel (administered at a starting dose of 75 mg/m2; at the
discretion of the investigator, the dose could be increased
to 100 mg/m2 if the side-effect profile was acceptable),
compared with placebo plus trastuzumab and docetaxel (at
the same doses). The final findings resulted in significant
reduction in the risk of progression or death and an in-
crease of 6.1 months in median PFS (18.5 vs 12.4 months,
p < 0.001).
The CLEOPATRA trial changes the clinical practice.
We now have a new standard of care for advanced dis-
ease espressing HER2. In any country of the world, for
patients with HER2 positive MBC the proposal for treat-
ment should include dual targeting with pertuzumab
and trastuzumab plus docetaxel or paclitaxel. The find-
ings of this study are really outstanding, because
showed a median OS of 56.5 months that is unprece-
dented in first-line MBC with an improvement in terms
of OS of 15 months respect to trastuzumab alone.
Who were the patients of Cleopatra study?
If we analyze the demographic characteristics of the
patients treated in Cleopatra study [32], we notice that
there is no difference in terms of results among pa-
tients who had previously received adjuvant/neoadiu-
vant chemotherapy and the patients with de novo
metastatic disease. Although the number of patients
who received prior neo-adjuvant treatment with trastu-
zumab was small, the benefit in terms of PFS achieved
with double block plus docetaxel in this population
was similar to that observed in subgroup not receiving
previous neo- or adjuvant therapy (p = 0.36).
Another intriguing aspect is the age of Cleopatra’s
patients: the median age was 54 years (range 27–89); in
the subgroup analysis by older age (>65 or <65) all the
patients showed a benefit in terms of PFS and OS in
favour of the dual block. In patients over 75 years no
significant difference were observed (p = 0.76).
With regard to the biological characteristics of the dis-
ease, both in triple positive tumors (expression of both
hormonal receptors [HRs] and HER2) and HER2-like
tumors (not expression of HRs and HER2 positivity), all
patients obtained a clinical benefit in terms of PFS and
OS in dual targeting arm, but the greatest benefit is
expressed in the HER2-like disease [0.61 (0.47–0.81)].
Also the visceral disease seems to get a better PFS, but
the number of patients with non-visceral disease was
very limited, and therfore no defined considerations it is
possible to drive.
The safety profile of pertuzumab, trastuzumab and
taxane was consistent with the known safety of patients
with long-term exposure to dual targeting. It means that
we now have a treatment that improves both PFS and
OS without affecting the QoL of patients in terms of
haematological, not haematological and cardiac safety.
This information is very important for the long duration
of exposure to the two biological molecules which the
patient can support.
Blockade of HER2 and not only
Constitutive activation of PI3K/AKT/mTOR signalling
due to PTEN loss can lead to trastuzumab resistance.
mTOR inhibition sensitises PTEN-deficient tumours to
trastuzumab, thereby suggesting that the combination of
everolimus, the mTOR inhibitor, and trastuzumab have a
role in the treatment of HER2-overexpressing BC [35, 36].
The addition of the mTOR inhibitor, everolimus, to
trastuzumab and chemotherapy showed clinical bene-
fit in heavily pretreated patients with HER2-positive
MBC progressing on previous trastuzumab and taxane
therapy [37].
No so high enthusiasm was declared when the two
target combination was tested in first-line MBC. In
Bolero 1 trial, patients were randomly assigned to re-
ceive either everolimus 10 mg once a day orally or pla-
cebo plus weekly trastuzumab intravenously (4 mg/kg
loading dose on day 1 with subsequent weekly doses of
2 mg/kg of each 4 week cycle) and paclitaxel intravenously
(80 mg/m2 on days 1, 8, 15 of each 4 week cycle) [38].
This study showed that the addition of everolimus to
trastuzumab plus paclitaxel did not improve clinical
outcomes. In the entire population, median PFS was
15 months (95 % CI: 14.55-17.91) with everolimus arm
versus 14 months with placebo arm (HR 0.89, 95 %
CI:0.73-1.08; p = 0. 11). In the HRs negative subpopula-
tion, median PFS with everolimus arm was 20 months
(95 % CI: 14.9-24.0) versus 13 months (10.0-16.5) with
placebo arm (HR 0.66, 95 % CI: 0.48-0.91; p = 0.004);
There was a clinically relevant prolongation of PFS with
the addition of everolimus in HRs negative patients
(7 months), but the p value did not meet prespecified
criteria for significance by a small margin. However,
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based on the statistical design, the threshold for statis-
tical significance in the HRs-negative subpopulation
was rather stringent (p = 0.0044) [39]. This result in the
HRs-negative patients are consistent with the previously
reported predefined subgroup analysis in BOLERO-3
wherein patients with HRs negative and HER2 positive
MBC derived more benefit when everolimus was added to
HER2- targeted treatment in the absence of hormonal
therapy [38].
Two ongoing phase 1 trials are assessing the benefits
of adding PI3K/mTOR inhibitors to endocrine therapy
and HER2-targeted therapy as first-line treatment in
patients with both HRs and HER2-positive advanced
BC. Mayer and colleagues are investigating the combin-
ation of an α-specific PI3K inhibitor BYL719 plus letro-
zole and trastuzumab (NCT01791478) and Wheler and
colleagues are assessing everolimus plus letrozole and
trastuzumab (NCT02152943). Further investigations of
these compounds in the HR-negative sub-population
are also of interest.
What about T-DM1 in the first-line treatment?
Despite the substantial activity of trastuzumab, resistance
to therapy arises in the majority of patients with advanced
disease, so there is a continued need to develop novel
agents to target HER2-amplified progressive disease.
Evidence that HER2-directed therapies are most effect-
ive when combined with cytotoxic chemotherapy, led
researchers to develop a novel antibody–drug conjugate,
T-DM1, in which highly potent maytanisinoid chemo-
therapy is stably linked to the HER2-targeted monoclo-
nal antibody, trastuzumab [40, 41].
Recently, T-DM1 has been approved by the European
Medicines Agency (EMA) and by the Food and Drug
Administration (FDA), as a single agent for the treat-
ment of patients with HER2-positive locally advanced
and unresectable or MBC, who have previously received
taxane- and trastuzumab-based treatment, separately or
in combination [42].
The mechanism of action of this molecule is very
exciting. Once T-DM1 binds to the extracellular domain
of HER2, the complex is internalized into the cell, where
the antibody is degraded by proteases, releasing the
active metabolite, lysine-Ne -MCC-DM1, into the cyto-
plasm. Because this metabolite is a charged molecule, it
is relatively membrane impermeable, reducing the possi-
bility that the DM1 could enter a neighboring cell, thus
further limiting the potential for nonspecific toxicity. In
addition to its ability to deliver DM1 selectively to tumor
cells, T-DM1 retains the effector functions of trastuzumab,
including inhibition of HER2-mediated signal transduction
and activation of antibody-dependent cellmediated cyto-
toxicity. Therefore, T-DM1 through this mechanism, leads
to a double antitumor effect, an anti-HER2 effect mediated
by the trastuzumab activity and a selective transport of a
powerful antimitotic agent DM1 to the intracytoplasmic
area. This innovative and selective mechanism of action
increases the efficacy while, at the same time, it reduces
the toxicity [42].
In preclinical experimental studies, T-DM1 induces a
cell-cycle arrest and apoptosis in HER2 positive cancer
cells but has little effect on HER2-negative cells. T-DM1
demonstrates activity in both trastuzumab and lapatinib-
resistant HER2 positive cancer models [43, 44].
The evidence of clinical activity of T-DM1 in HER2
MBC was demonstrated in the phase III EMILIA trial
[45] in which pretreated patients with one or two lines
of trastuzumab-including chemotherapy were assigned
to receive either lapatinib (1250 mg daily continu-
ously p.o.) plus capecitabine (1000 mg/m2 p.o. twice a
day, 14 days on, 7 days off ) or T-DM1 every 3 weeks.
The primary end point was achieved with the median
PFS of 9.6 months in the T-DM1 group versus
6.4 months in the lapatinib plus capecitabine group
(HR 0.65; 95 % CI: 0.55–0.77; P = 0.001). Median OS
crossed the stopping boundary for efficacy and was in-
crease by 5 months in the T-DM1 group (31 months
versus 25 months; HR 0.68; 95 % CI, 0.55–0.85; P =
0.001). Secondary endpoints including ORr (43.6 %
versus 30.8 %; p = 0.001) and median DR (12.6 months
versus 6.5 months) favored T-DM1. In addition, the
median time to decrease of 5 points or more in the
Functional Assessment of Cancer Therapy-Breast
(FACT-B TOI) score was delayed in the T-DM1-
treated patients (7 months versus 4.6 months; HR
0.80; 95 % CI:0.67–0.95; P = 0.012). A further analysis
of patients who had not a first-line treatment demon-
strated a significant additional benefit in terms of PFS
in favor of the new molecule (10.3 vs 6.7 months).
In February 2013, after EMILIA results, T-DM1 was
approved by FDA as a treatment for HER2 positive pre-
treated MBC.
The next step after Emilia results was to evaluate
T-DM1 in the first line choice. A phase 2 randomized
trial (TDM4450g) compared three-weekly T-DM1 to
three-weekly docetaxel plus trastuzumab in 137 patients
with previously untreated HER2 positive MBC [46].
Patients in the control group received trastuzumab plus
docetaxel (75 or 100 mg/m2, per investigator choice). The
ORr (58 % in the control group versus 64 % in the T-DM1
group; p = 0.458) and clinical benefit rate were similar in
the two treatment groups; however, T-DM1 was associ-
ated with a significant 5 months prolongation in median
PFS (9 months versus 14 months; HR: 0.59; 95 % CI:
0.36–0.97). Interestingly, there was a much lower rate of
grade 3/4 serious adverse events with T-DM1 group
occurring in 58 % of patients in the control arm group
compared with only 6 % in the T-DM1 group. In the
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docetaxel/trastuzumab group, the most common toxic-
ities were alopecia, neutropenia, diarrhea, and fatigue
and more patients used colony-stimulating factors; a
very different adverse events occorred in TDM-1
group, such as fatigue, nausea, elevated serum aspar-
tate aminotransferase, fever and headache. A lower rate
of adverse events in the T-DM1 group translated to an
improvement in quality of life [46].
Unfortunately, patients experience disease progression
on T-DM1; hence, discovering molecular markers that
can predict response or resistance to this molecule
remains a high priority.
The results from combination of T-DM1 + pertuzu-
mab in synergistic inhibition of tumor cell line prolifer-
ation in vitro, provided the rationale for further study.
In MARIANNE trial [39], 1095 patients with pro-
gressed or recurrent locally advanced or previously un-
treated metastatic HER2-positive BC were assigned to
receive T-DM1 plus pertuzumab, T-DM1 plus placebo
or trastuzumab plus docetaxel/paclitaxel (control arm).
At the time the trial was initiated, the control arm repre-
sented the standard of care for this patient population.
After a median follow-up of 35 months, both T-DM1–
containing regimens showed noninferior PFS, but not
superiority, over control arm. The median PFS was
15 months in the T-DM1 plus pertuzumab arm (HR:
0.87, 95 % CI: 0.69-1.08; p = 0.14), 14 months with T-
DM1 alone (HR 0.91, 95 % CI :0.73-1.13; p = 0.31) com-
pared with 13.7 months with trastuzumab and taxane.
The OS data were not yet reached. The objective re-
sponse rate was 64 %, 60 %, and 68 % among the three
schedules, respectively. However, the median duration of
response was 21 months both in the T-DM1 plus pertu-
zumab arm and in the T-DM1 alone arm, and
12.5 months in the control arm. This unexpected result
has induced researchers to review projects of trials in
course.
So, for the time being, Cleopatra regimen remains the
preferred first-line therapy for HER2-positive MBC, and
the treatment guidelines for 2016 remain unchanged.
Vertical blockade in first-line: is there a position
for it?
Dual inhibition targeting both intracellular and extracel-
lular domain of HER2 has also been tested in metastatic
HER2 positive BC, as demonstrated by preclinical stud-
ies in HER2-positive cell lines, that shown a synergistic
interaction between lapatinib and trastuzumab [47].
In the phase III EGF104900 trial, a heavily pretreated
patients which had progressed on prior trastuzumab-
based regimens was randomly assigned to receive
combination of lapatinib and trastuzumab or lapatinib
monotherapy [48]. In the intent-to-treat population
who received a median of three prior trastuzumab-
containing regimens, the combination of lapatinib with
trastuzumab versus lapatinib alone significantly im-
proved PFS (HR: 0.73; 95 % CI: 0.57-0.93; P =0.008)
and clinical benefit rate (25 % in the combination arm
versus 12 % in the monotherapy arm; p = 0.01), thus
offering a chemotherapy-free option with an
acceptable safety profile to patients with HER2-
positive MBC. In the final survival analysis, dual HER2
blockade led to significant 4.5-months improvement in
OS (HR: 0.74, 95 % CI: 0.57–0.97, P = 0.026) in the
HER2 positive MBC [48]. A small cohort of untreated
HER2 positive patients for metastatic disease received
Chemotherapy-free treatments as in first-line treat-
ment. Median OS was 43 months and median persist-
ence on protocol was 3.8 months, with 4 patients
(21 %) persisting on single agent for longer than
12 months. The gene expression analysis revealed that
high expression of the 17q12-21 amplicon genes HER2
and GRB7, and the PAM50 HER2-enriched intrinsic pro-
file, were significantly associated with longer persistence
on protocol. Conversely, high expression of luminal-
related genes such as PGR, MDM2 or PIK3CA, or the
PAM50 luminal intrinsic profile correlated with reduced
persistence on protocol. Moreover, increasing H2T/p95
ratio was found to be significantly associated with longer
persistence on protocol (HR 0.56 per 2-fold increase in
H2T/p95, p = 0.0015) [49].
The data suggest that patients belonging to the “HER2-
enriched” subtype and/or having high H2T/p95 protein
expression ratio are exquisitely sensitive to anti-HER2
agents. MBC patients with these tumors could be candi-
dates for studies aimed at establishing chemotherapy-free
regimens also in early metastatic disease.
Based on the evidence in the literature, there is defin-
itely a subset of patients who may benefit from treat-
ment with trastuzumab and lapatinib, particularly when
given in combination. This research aims to evaluate
prospectively the efficacy of trastuzumab or lapatinib as
a single agent in a population of patients carefully
selected for the presence of HER2 amplification in the
tumor.
It is clear that an adeguate selection of patients for
treatment with trastuzumab and either lapatinib could
allow an optimization of available resources to ensure
optimal patient treatment.
Nevertheless, a deeper understanding of the mecha-
nisms of action of trastuzumab, especially action tied
to antibody-mediated cytotoxicity (ADCC), may allow a
better selection of patients based on molecular genetic
markers predictive of response. In order to define activity
and to identify biomolecular factors predictive of resis-
tence to double HER2 blocked, a phase II study for
untreated HER2 positive MBC patients with the use
of trastuzumab plus lapatinib for 8 weeks continuing
Fabi et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:104 Page 5 of 11
for further 8 weeks in case of response is ongoing
[NCT00842998].
Pan-HER tirosin kinase inhibitor: towards
neratinib
In the recent years, a new group of compounds that bind
irreversibly to the adenosine triphosphate binding pocket
of HER receptors have been developed. One of these
compounds, neratinib, has passed preclinical phases and
is currently undergoing various clinical trials. Import-
antly, pan-HER TKI are very attractive strategies for this
purpose. Among them, JNJ-28871063 has been shown
preclinically to penetrate the blood barrier brain (BBB)
more effectively than lapatinib, being also effective in
improving survival of xenograft mouse models with
HER2 positive intracranial metastases [50]. Neratinib, is
another pan-HER TKI that is under clinical development
fro HER2 positive BC which could prove highly effective
also on central nervous system (CNS) metastases [51].
To date no date are evaluable about Neratinib activity in
early recurrence brest disease. A trial in which the pan-
HER inhibitor is compared with lapatinib plus capecita-
bine in HER2 positive patients previously treated with
trastuzumab for MBC, is ongoing. Recently was presented
preliminary results of randomized EXTENT study, in
HER2 positive patients in which Neratinib was given after
the completention of trastuzumab in adjuvant setting. The
findings showed that Neratinib significally improved
disease-free interval when compared with no further anti-
HER2 adjuvant therapy [51]. After results of ongoing
evidence of efficacy in second-third line therapy, probably
neratinib could have an interesting position for first-line
treatment in HER2 postive MBC patients.
When the cancer expresses hormonal receptors
Hormonal therapy and trastuzumab represent one of the
oldest and one of the newest treatment modalities for BC,
respectively. Recent data have suggested that HER2
overexpression is associated with resistance to hormonal
therapy and there is considerable preclinical evidence to
support the existence of interaction or cross talk between
HER2 and estrogen-receptor signalling pathways in BC.
Preclinical data also demonstrate that adding trastuzumab
to hormonal therapy results in greater antitumour activity
than either agent alone. The existence of an inverse rela-
tionship between estrogen receptors ER expression and
HER2 overexpression has also been well established clinic-
ally. Thus, a range of clinical trials are now ongoing to de-
termine whether the addition of trastuzumab to hormonal
therapy will provide BC patients with benefits in clinical prac-
tice. For patients with bone-only spreading disease and indo-
lent disease progression, the combination of anti-HER2 and
endocrine therapy as first-line treatment represents a valid
therapeutic option. Three trials have examined the addition
of HER2-targeted agents to aromatase inhibitors (AI) in post-
menopausal women with a first recurrence (Table 1).
In the TANDEM study, 207 patients were randomized
to anastrozole (1 mg daily) plus trastuzumab (4 mg/kg
loading dose, followed by 2 mg/kg weekly) or to anastro-
zole alone [52]. The combination arm was associated with
an improvement in PFS (4.8 months vs. 2.4 months; HR
0.63) and an irrelevant improvement in OS (28.5 months
vs. 24 months). Also the response rate was in favour of the
combination therapy (20 vs. 7 %). The most common
toxicities seen in the combination arm were fatigue
(21 %), vomiting (21 %), and diarrhea (20 %); however, the
vast majority of events were grades 1 and 2.
The combination of letrozole plus trastuzumab was
compared with letrozole alone in the Electra study [53];
fifty-seven postmenopausal patients were randomized to
receive letrozole (2.5 mg daily) with or without trastuzu-
mab (4 mg/kg loading dose, followed by 2 mg/kg weekly).
In addition, HER2-negative patients were enrolled as a
third cohort and were treated with letrozole alone. The
trial experienced slow accrual and closed early, before the
planned 370 patients could be enrolled. Nevertheless, the
addition of trastuzumab to letrozole was associated with a
significant improvement in TTP (14 months vs. 3 months;
HR: 0.67), the duration of which was similar to the dur-
ation achieved in the HER2-negative group (15 months).
The rates of response and clinical benefit were 27 vs
13 % and 65 vs 39 %, respectively, in favour of both
trastuzumab-containing arm.
A third study, EGF30008, compared the all-oral com-
bination of letrozole (2.5 mg daily) and lapatinib
(1500 mg daily) with letrozole alone [54]. Of the almost
1300 patients enrolled, about a quarter of them had
hormonal receptors [HRs] and HER2 positivity. In that
subgroup, the addition of lapatinib to letrozole was associ-
ated with a significant improvement in PFS (8 months vs
3 months: HR: 0.71) and response rate (28 vs 15 %). Over-
all survival was not significantly different (33 vs 32 months).
As previously seen with lapatinib, diarrhea was significantly
more common in the combination arm (grade 3 and 4
diarrhea: 10 vs 1 %).
On Table 2 are reported ongoing clinical trials evaluating
new anti-HER2 molecules combined with hormone therapy
in first-line setting. PERTAIN is a randomized phase II trial
conducting since 2012, exploring the combination of an
aromatase inhibitor with trastuzumab and pertuzumab vs
an aromatase inhibitor with trastuzumab in first line treat-
ment of HR positive/HER2 positive advanced disease in
postmenopausal setting [NCT01491737].
The DETECT V/CHEVENDO trial is a randomized
phase III study which aims to compare the combin-
ation of trastuzumab, pertuzumab and a chemotherapy
drug (docetaxel, paclitaxel, capecitabine or vinorelbine)
with the combination of trastuzumab, pertuzumab and
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hormonal therapy (tamoxifen, fulvestrant, letrozole or
anastrozole). It is an ongoing trial currently recruiting
participants [NCT02344472]. Finally, the phase II
1303GCC trial will compare trastuzumab in combin-
ation with pertuzumab alone vs trastuzumab, pertuzu-
mab and eribuline vs trastuzumab, pertuzumab and
hormonal therapy (anastrozole or fulvestrant) in locally
advanced or metastatic BC affecting patients aged 60
or more [NCT02000596].
Although for patients with HRs/HER2 positive disease
improvements in TTP or PFS were seen with the
addition of anti-HER2 molecules to endocrine therapy,
the gains are modest, and no study has demonstrated an
improvement in OS. Hence, the use of such approaches
has to be weighted against the significant benefit in PFS
and OS seen when anti-HER2 molecules are combined
with chemotherapy as outlined earlier.
Is there a treatment of choice for early brain
metastases from HER2 positive breast cancer?
CNS progression is a frequent phenomenon in
trastuzumab-treated patients. Whether or not it reflects
the lack of penetration of trastuzumab through the
blood brain barrier or a higher propensity of HER-2
positive disease to spread into the CNS, it is reason-
able to continue trastuzumab in the subgroup of pa-
tients who develop CNS metastases as the only site
of disease progression, since increasing evidence sug-
gests a benefit in terms of OS for patients continuing
trastuzumab after receiving radiotherapy for intracra-
nial disease [55, 56]. On the other hand, lapatinib has
been shown to be active in CNS metastases of HER2
positive patients, although its role in this setting requires
further testing in clinical trials [57].
An important challenge is the prevention of CNS
metastases in HER2 positive metastatic disease For the
first time, in the recent CEREBEL study [58] patients
with HER2- positive MBC without brain metastases
were randomized to compare trastuzumab-capecitabine
versus lapatinib-capecitabine in order to evaluate the
incidence of CNS metastases as first site of relapse.
Patients enrolled onto CEREBEL had similar popula-
tion characteristics to those reported in other large
prospective clinical trials of HER2-positive MBC that
Table 1 Studies with anti-HER2 molcules plus hormonal therapy in the first-line metastaic breast cancer
Author N. of patients Treatment PFS (months) OS (months) Response Rate (%)
Kaufman et al. 2009 (TANDEM study) 207 Anastrozole 1 mg po daily + T iv (4 mg/kg
loading dose, then 2 mg/kg weekly)
4.8 28.5 21
Anastrozole 1 mg po daily 2.4 (p = 0.002) 23.9 (p = 0.325) 7 (p = 0.018)
Huober et al. 2012 (ELECTRA) 92 Letrozole 2.5 mg po daily + T iv (4 mg/kg
loading dose, then 2 mg/kg weekly)
14.1 NR 27
Letrozole 2.5 mg po daily 3.3 (p = 0.23) NR 13 (p = 0.002)
Johnston et al. 2009 (EGF30008) 263 Letrozole 2.5 mg po + Lapatinib 1500 mg
po daily
8.2 33.3 28
Letrozole 2.5 mg po + placebo po daily 3.0 (p = 0.019) 32.3 (p = 0.113) 15 (p = 0.021)
PFS progresson free survival, OS overall survival, T trastuzumab
Table 2 Ongoing studies of first-line treatments for HER2 positive metastatic breast cancer
Study Arms of Treatment Population N. of patients Obiectives of Study
Peruse (MO28047) P + T + Tx mBC HER 2+ 1436 Multicenter clinical practice, single-arm phase IV study to
evaluate the safety of the combination in real life world
Pertain (MO27775) P + T + AI vs T + AI mBC HER2+ HR+
Post menopausal status
250 Randomized multicenter open label phase II study
designed to assess the efficacy and safety of P+ T + AI
[anastrozole or letrozole) or T+ AI. Pts in either arm may
also receive induction chemotherapy for up to 18 weeks
at the investigator’s discretion.
Velvet (MO27782) P + T + VNR mBC HER2+ 210 Randomized, multicenter open-label, single-arm with 2
cohorts of patients (cohort 1 = sequential infusion of P and
T; cohort 2 concomitant P and T) designed to evaluate the
efficacy and safety of P in combination with VNR
Metapher (BO29159) P + T (s.c) + Tx mBC HER2+ 400 Multicenter single-arm phase IIIb study, designed to
evaluate the safety and efficacy of the combination
P + T subcutaneously + Tx
P Pertuzumab, T Trastuzumab, Tx Docetaxel or Paclitaxel or nabPaclitaxel, VNR Vinorelbine, AI aromatase inhibitor, mBC metastatic Breast Cancer, s.c. subcutaneous
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used a capecitabine combination [57, 59, 60] with the
exception of the proportion of patients previously
exposed to trastuzumab, with more patients who were
trastuzumab naive in CEREBEL trial. The study was
inconclusive for its primary end point and was unable
to demonstrate the prevention of CNS metastases by
lapatinib-capecitabine compared with trastuzumab-
capecitabine. A better outcome of disease in the
entire population was observed in the trastuzumab-
capecitabine arm [58]. However, lapatinib-capecitabine
efficacy may have been affected by previous exposure to a
trastuzumab regimen and/or when treatment was given as
first- or second-line therapy in the metastatic setting.
Recent findings, revealed intersting activity of T-DM1
in HER2 postive patients with brain metastasis, also in
that case without any loco-regional treatment for CNS
recurrences. Probably T-DM1 therapy might be able to
prevent out-growth to macro-metastases. In addition, T-
DM1 could be useful for patients with established brain
metastases that qualify for primary systemic therapy,
although WBRT is likely to become necessary eventually
[61, 62].
Still, these results suggest that ongoing investigation of
T-DM1 in brain metastases is warranted.
Recently an interesting finding has been highlighted
with the use of neratinib. The phase 2 study NeferTT
compared paclitaxel associated with trastuzumab or
neratinib in a cohort of 479 HER2 positive patients.
Despite the result in terms of PFS was not in favour of
either treatment arms, in the group treated with Nerati-
nib the incidence of symptomatic brain metastases was
significantly lower (8 vs 17 %, RR0.48, p = 0.002), as well
as a follow up of two years relapse of disease at CNS
was much lower (16 vs 31 %, p = 0.0036) [63]. Neratinib
could have a potential role in patients at risk for CNS
metastatic events. To investigate further the efficacy of
neratinib in metastatic ERBB2-positive breast cancer, the
National Surgical Adjuvant Breast and Bowel Project
(NSABP) Foundation has recently initiated a phase 1b/2
study of neratinib in combination with ado-trastuzumab
emtansine as second-line therapy (NCT02236000).
Limitations of the research include the lack of specific
data on patients with HER2-positive brain disease, how to
measure efficacy of various chemotherapy agents and of
anti-HER2 molecules. When there is a lack of multiple ro-
bust comparative studies, this precludes recommendations
on the basis of high-quality evidence [64].
The future landscape in first-line treatment for
HER2 positive disease
In Table 3 are showed the ongoing randomized studies
in first-line advanced disease.
Recently, preliminary results on safety of IIIb PERUSE
trial (NCT01572038) [65] were showed; the study is
assessing the safety of first-line pertuzumab plus trasu-
zumab associated to investigator’s chosen taxane [doce-
taxel (45 %), paclitaxel (47 %), or nab-paclitaxel (6 %)] in
routine clinical practice. To the first analysis, therapy
was discontinued most often for progression disease
(pertuzumab 7 %, trastuzumab 7 %, taxane 4 %) and for
AEs in 4 % (each agent). The safety profile of the study
is consistent with previous clinical experience of Cleo-
patra trial, and no unexpected safety signals were seen
[65]. It is in course of enrollment a multicenter inter-
national single-arm, clinical practice study, commis-
sioned by EMA, to evaluate the safety of the
combination in the real life world.
PERTAIN trial (NCT01491737) is looking at combin-
ing pertuzumab with trastuzumab and an aromatase
inhibitor to treat HER2/HR positive advanced BC; The
trial want to find out how safe the combination of pertu-
zumab, trastuzumab and an aromatase inhibitor is and
the activity of the double anti HER2 block with endo-
crine therapy in postmenopausal patients.
In order to test the introduction of different che-
motherapic agents from taxane therapy in association
with pertuzumab and trastuzumab, phase II VELVET
study (NCT01565083) is enrolling patients receiving or
the two anti-HER2 molecule as separate infusion or
receiving pertzumab and trastuzumab in single saline
infusion bag after the first cycle.
To date is not investigated the subcutaneous trastuzu-
mab administretion in association with pertuzumab.
METAPHER trial (NCT02019277) is a multicenter, inter-
national, single-arm post licence investigation that was
designed in order to evaluate the safety and efficacy of the
combination with pertuzumab plus trastuzumab subcuta-
neously associated to taxane.
Conclusions
In HER2 positive disease the use of trastuzumab is well
established. The strong recent data clearly recommend
the early use of pertuzumab in combination with trastu-
zumab and paclitaxel or docetaxel in MBC and ongoing
trial will define the integration in the adjuvant setting of
these double HER2 inhibition. The mandatory use of
this combination in first-line metastatic setting is regard-
less of the site of the disease concerned. Although we do
not have today any results regarding the activity of
pertuzumab in population that develops early brain
metastases, there is prelimnary evidence of a delayed on-
set of the CNS spreading with the inclusion of pertuzu-
mab treatment to the standard HER2 double biological
therapy. An attrattive field of research would be the
response of double block on CNS metastases at the first
recurrence of disease.
Positive data support the combination of trastuzu-
mab and endocrine agents in that case in which is
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not well indicated chemotherapy incuding agents,
such as elderly patients, indolent progressive disease,
absence of visceral crisis. Actually, we have no data
to support the use of HER2 double block plus hor-
monal therapy in selective cases with first recurrence
of disease.
Unfortunately, all the HER-2 positive MBC patients
will eventually develop resistance to pertuzumab plus
trastuzumab and taxanes, or to trastuzumab combined
with endocrine therapy, even those who initially benefit
from the treatment.
No other anti HER2 biological agents showed better
efficacy than pertuzumab and trastuzumab in first-line
therapy. T-DM1 seems to offer improved safety and effi-
cacy over two widely used treatments for HER2-positive
MBC. T-DM1-associated adverse reactions were gener-
ally manageable with appropriate dose modification and
supportive care. The safety profile in first-line MBC or
early BC is expected to be similar, and clinical trials are
under way to evaluate T-DM1 in these settings.
There is an urgent need for prospective biomarker-
driven trials to identify patients for whom dual HER2
targeting is cost-effective [66–68].
In conclusion, pertuzumab associated to trastuzumab
represents now the milestone of first therapeutic approach
in HER2 postive subtypes tumor, and the benefit in terms
of outcome disease achieved with “Cleopatra treatment” is
one of the more deep enthusiastic result obtained in the
story of MBC cure.
Finally, the research has focused on molecular mecha-
nisms underlying resistance to trastuzumab and pertuzu-
mab. However, there is still much that we need to lern,
in particular to better define activity correlated with bio-
markers that could be define resistence or sensitivity to
the specific target molecule.
The future is one in which it will be possible to use an
ample armamentarium of combination therapies directed
against HER2 and key signaling components integrated in
the HER network. This therapeutic approach will allow
clinicians to tailor the clinical management of the individ-
ual patient on the basis of tumor-specific biomarker pro-
files, as captured at the time of diagnosis and in the
course of treatment.
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